SLAM
NBIX icon

Swiss Life Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Swiss Life Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.8M Buy
58,156
+37,416
+180% +$5.55M 0.04% 318
2026
Q1 		$2.73M Buy
20,740
+1,991
+11% +$264K 0.01% 508
2025
Q4 		$2.66M Buy
18,749
+982
+6% +$142K 0.01% 520
2025
Q3 		$2.49M Buy
17,767
+4,293
+32% +$582K 0.01% 537
2025
Q2 		$1.69M Sell
13,474
-1,496
-10% -$172K 0.01% 572
2025
Q1 		$1.66M Buy
14,970
+4,585
+44% +$581K 0.01% 531
2024
Q4 		$1.42M Buy
10,385
+6,740
+185% +$834K 0.01% 533
2024
Q3 		$420K Sell
3,645
-316
-8% -$43.3K ﹤0.01% 560
2024
Q2 		$545K Buy
+3,961
New +$543K 0.01% 483
2024
Q1 		– Sell
-5,954
Closed -$785K – 595
2023
Q4 		$785K Sell
5,954
-19,806
-77% -$2.28M 0.01% 516
2023
Q3 		$2.9M Buy
25,760
+21,232
+469% +$2.24M 0.04% 387
2023
Q2 		$427K Buy
4,528
+1,895
+72% +$185K 0.01% 574
2023
Q1 		$267K Buy
2,633
+117
+5% +$12.2K ﹤0.01% 590
2022
Q4 		$301K Buy
+2,516
New +$295K 0.01% 565

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return

Swiss Life Asset Management's NBIX Position: Q2 2026 in Review

Swiss Life Asset Management increased its Neurocrine Biosciences (NBIX) stake by 180% in Q2 2026, buying an estimated $5.55M and bringing the position to 58,156 shares worth $9.8M. The position accounts for 0.04% of the portfolio, ranked #318.

Swiss Life Asset Management first reported a position in NBIX in Q4 2022 and has held it in 14 quarters since. 526 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Swiss Life Asset Management held 58,156 shares of Neurocrine Biosciences worth $9.8M as of Q2 2026.
  • Swiss Life Asset Management bought 37,416 Neurocrine Biosciences shares in Q2 2026, an estimated $5.55M.
  • Neurocrine Biosciences made up 0.04% of Swiss Life Asset Management's portfolio in Q2 2026, its #318 holding.
  • Swiss Life Asset Management first reported a position in Neurocrine Biosciences in Q4 2022 and has held it in 14 quarters since.
  • 526 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Swiss Life Asset Management's 13F filing for Q2 2026, filed 29 Jul 2026.